# CONTENTS - VOLUME XI, 1985


**No. 1**

Anthracycline mechanisms in analogue selection.
ACTON E.M. ..... 1

Experimental studies on aclacinomycin.
TONE H., NISHIDA H., TAKEUCHI T., UMEZAWA H. ..... 9

Clinical review of aclacinomycin A in Japan.
OTA K. ..... 17

Methicillin- and gentamicin-resistant *Staphylococcus aureus*: susceptibility to fosfomycin, cefamandole, N-formimidoyl-thienamycin, clindamycin, fusidic acid and vancomycin.
GRANINGER W., LEITHA T., BREYER S., FRANCESCONI M., LENZ K., GEORGOPOULOS A. ..... 23

Cefmetazole: a broad spectrum cephem antibiotic effective on methicillin- and cephem-resistant *Staphylococcus aureus*.
YOKOTA T., YOSHIDA R., UTSUI Y., TAJIMA M. ..... 29

*In vitro* antibacterial activity of imipenem against *Pseudomonas* and *Staphylococcus* species. Comparison with thirteen other antimicrobial agents.
CRISTIANO P., ABBATE G.F., ALAGIA I., LEONESSA V., GIAQUINTO E., SAVIOLI L. ..... 39

Study on the antibacterial activity of ceftazidime in an *in vitro* pharmacokinetic model.
XERRI L., BROGGIO R. ..... 49

Experimental endocarditis and fosfomycin.
RODRÍGUEZ A., VICENTE M.V., OLAY T. ..... 55

Cigarette smoke and N-acetylcysteine: interference with the bactericidal properties of serum.
MARCA G., PINASI C., BELLUCO G., CARENZI A. ..... 63

Effect of amantidine on rhabdovirus infection.
SUPERTI F., SEGANTI L., PANÀ A., ORSI N. ..... 69

**No. 2**

*In vivo* and *in vitro* immunomodulatory ability of streptococcal mitogen: effects on adjuvant disease in the rat; on homograft rejection in the mouse; and on the appearance of Ia antigens on human T lymphocytes.
QUAGLIATA F., FERRONE S., TARANTA A. ..... 75

The influence of some cephalosporins on immunological response.
BOROWSKI J., JAKONIUK P., TALARCZYK J. ..... 83

The effect of control on the pattern of utilization of cefotaxime, moxalactam and cefoperazone in a teaching hospital.
MA M.Y., RHO J.P. ..... 89

Norfloxacin in prostatitis: correlation between HPLC tissue concentrations and clinical results.
BOLOGNA M., VAGGI L., FLAMMINI D., CARLUCCI G., FORCHETTI C.M. ..... 95

Urinary tract infections after renal transplantation.
ALEXOPOULOS E., MEMMOS D., SAKELLARIOU G., PASCHALIDOU E., KYROU A., PAPADIMITRIOU M. ..... 101

Topical use of PVP-I (betadine) preparations in patients with spinal cord injury.
MICHAEL J. ..... 107

Peroperative systemic prophylaxis in colorectal surgery.
HAVERKORN M.J. ..... 111

Studies on the effects on anthracyclines on mitochondiral respiration *in vitro*.
SOLAINI G., RONCA G., BERTELLI A. ..... 115

Aclarubicin: experimental and clinical experience.
RÖTHIG H.-J., KRAEMER H.P., SEDLACEK H.H. ..... 123

The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
MARTONI A., PACCIARINI M.A., PANNUTI F. ..... 127

On the differential affinities of two anticancer analogues to their target.
HOLL E., ZÄNKER K.S., LANGE J., SIEWERT J.R. ..... 133

Combined polychemotherapy in the treatment of primitive lung cancer of the "non-oat cell" type.
TAGLE J.C., GÁLVEZ C.A., BARG S., TEMPERLEY G.J. ..... 141

**No. 3**

Effect of pH on the morphology of *Staphylococcus aureus*.
MIRZA J., KIM Y., LORIAN V. ..... 149

An assay for screening drugs against animal-infective bloodstream forms of *Trypanosoma brucei brucei in vitro*.
BOROWY N.K., HIRUMI H., WAITHAKA H.K., MKOJI G. ..... 155

Comparative *in vitro* activity of aztreonam and other antimicrobial agents against *Salmonella* species.
PARADELIS A.G., DELIDOU K., STRAVRAKIS A.O., CRASSARIS L.G. ..... 163

Pefloxacin: evolution of *in vitro* activity during 18 months of use in an intensive care unit.
TIGAUD S., MARCATELLO A., ROBERT D., GILLE Y., VINCENT P. ..... 169

Norfloxacin: a three-day course for the treatment of urinary tract infection.
GANGULI L.A., KEANEY M.G.L., GOULD L.J. ..... 177

Cefmetazole: clinical evaluation of efficacy and safety in Japan.
SHIMADA J., HAYASHI Y., NAKAMURA K. ..... 181

Clinical study with cefoxitin in paediatrics.
ROSASCHINO F., VITA C.R.G., BOSCO U., CASTELLI F., VERCELLONI M. ..... 195

Cefuroxime versus ceftriaxone prophylaxis in cardiovascular surgery.
GEROULANOS S., DONFRIED B., SCHUMACHER F., TURINA M. ..... 201

Molecular level studies with anthracyclines.
ECKLE E., KIEFER E., LAUSER G., STEZOWSKI J.J. ..... 207

Cardiotoxic effects of adriamycin and mitochondrial oxidation in rat cardiac tissue.
MONTALI U., DEL TACCA M., BERNARDINI C., SEGNINI D., SOLAINI G. ..... 219

Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.
VILLANI F., COMAZZI R., GENITONI V., LACAITA G., GUINDANI A., CRIPPA F., MONTI E., PICCINI F., ROZZA A., LANZA E., FAVALLI L. ..... 223

Preoperative chemotherapy in epidermoid bronchogenic carcinoma.
MORERE J.F., ISRAEL L., BREAU J.L., CLAVIER J., GUILLERM D., ZABBE C., RAUT Y., MORERE P., NOUVET G., LEREBOURS PIGEONNIERE G., GRES J.J., DAVID P. ..... 233

**No. 4**

Sensitivity testing of bacteria to ceftriaxone using discs with different amounts of antibiotic.
BOROWSKI J., JAKONIUK P., JAKUBICZ P., ROGALEWSKI M. ..... 237

Antibacterial activity *in vitro* of sulbenicillin against mucoid and non-mucoid strains of *Pseudomonas aeruginosa*.
EFTIMIADI C., DE LEO C., SCHITO G.C. ..... 241

N-formimidoyl-thienamycin and norfloxacin against multiple-resistant *Pseudomonas aeruginosa* strains. Combined *in vitro* activity and comparison with 14 other antibiotics.
MARTINO P., VENDITTI M., VALENTE B., BRANDIMARTE C., SERRA P. ..... 247

The comparative *in vitro* activity of twelve 4-quinolone antimicrobials against enteric pathogens.
O'HARE M.D., FELMINGHAM D., RIDGWAY G.L., GRÜNEBERG R.N. ..... 253

The comparative activity of twelve 4-quinolone antimicrobials against *Haemophilus influenzae* and *Streptococcus pneumoniae*.
RIDGWAY G.L., O'HARE M.D., FELMINGHAM D., GRÜNEBERG R.N. ..... 259

Clinical experience with miocamycin in the treatment of respiratory tract infections.
RIMOLDI R., FIORETTI M., BANDERA M. ..... 263

Experimental comparative renal toxicity of lithium and rubidium.
BERTELLI A., GIOVANNINI L., ROMANO M.R., MALTINTI G., DELL'OSSO L., BERTELLI A.A.E. ..... 269

Tissue distribution of methotrexate in rats. A comparison between intravenous injection as bolus or drip infusion.
MIGLIOLI P.A., BUSINARO V., MANONI F., BERTI T. ..... 275

Fluorescence in sections of cardiac muscle from rats acutely treated with 4'-0-tetrahydropyranil-adriamycin hydrochloride (THP).
MAZZANTI L., BRESCHI M.C., GIOVANNINI L., BERTELLI A.A.E. ..... 281

Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
CAMAGGI C.M., STROCCHI E., MARTONI A., ANGELELLI B., COMPARSI R., PANNUTI F. ..... 285

Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration.
STROCCHI E., CAMAGGI C.M., ROSSI A.P., ANGELELLI B., COMPARSI R., FRANCHINI A., DEL PRETE P., COLA B., PANNUTI F. ..... 295

Use of antisecretory drugs for gastroprotection during antiblastic chemotherapy.
POLLONI A., MARCHI S., BELLINI M., SAVALLI E., CECCONI N., VANACORE R., GRASSI B. ..... 303

Proglumetacin in arthritis of the hip and the knee. Results of a post-marketing surveillance study.
CARRATELLI L., ANTONINI P., MESSINA E., PICA B. ..... 307

**No. 5**

Comparative *in vitro* studies with 4-quinolone antimicrobials.
FELMINGHAM D., O'HARE M.D., ROBBINS M.J., WALL R.A., WILLIAMS A.H., CREMER A.W., RIDGWAY G.L., GRÜNEBERG R.N. ..... 317

Comparative *in vitro* activity of ciprofloxacin and five other quinoline derivatives against Gram-negative isolates.
GALANTE D., PENNUCCI C., ESPOSITO S., BARBA D. ..... 331

Influence of PH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
ZEILER H.-J. ..... 335

The pharmacology of orally administered ciprofloxacin.
BRITTAIN D.C., SCULLY B.E., McELRATH M.J., STEINMAN R., LABTHAVIKUL P., NEU H.C. ..... 339

Assessment of the *in vitro* and *in vivo* activity of ciprofloxacin measured against current standards of therapy.
ZEILER H.-J., METZGER K.G., SCHACHT P., GROHE K. ..... 343

Experience with ciprofloxacin in the treatment of various infections caused mainly by *Pseudomonas aeruginosa*.
GIAMARELLOU H., DAPHNIS E., DENDRINOS C., DAIKOS G.K. ..... 351

**No. 6**

Ultrastructure of staphylococci in respiratory infections treated with nafcillin
ERNST J., SY E., LORIAN V., KIM Y. ..... 357

Combined cefuroxime plus acetylcysteine in the treatment of bacterial infections of the respiratory tract
BONAVITA E. ..... 361

Position of ceftazidime in respiratory diseases
ANDO' F., GIRBINO G., FERRARA F. ..... 369

Behaviour of cefmenoxime towards beta-lactamases
LABIA R., MORAND A., BEN YAGHLANE H., BRYSKIER A. ..... 373

Effects of MT-141, a new cephamycin antibiotic, on acute urinary tract infections
MIYAMOTO S., TAMIYA T., TAKATSUKA K., KUMAMOTO Y. ..... 379

Comparison of rapid bacteriological response to MT-141 and latamoxef in complicated urinary tract infections
MIYAMOTO S., TAMIYA T., TAKATSUKA K., KUMAMOTO Y. ..... 383

A non-absorbable rifamycin for treatment of hepatic encephalopathy
TESTA R., EFTIMIADI C., SUKKAR G.S., DE LEO C., ROVIDA S., SCHITO G.C., CELLE G. ..... 387

*In vitro* sensitivity of *Malassezia* spp. to various antimycotics
LORENZINI R., MERCANTINI R., DE BERNARDIS F. ..... 393

Genetically engineered insulin: five years of experience
BROGARD J.-M., BLICKLE J.-F., PARIS-BOCKEL D. ..... 397

Antilipolytic activity of tiadenol-nicotinate in isolated fat cells: a comparison with its parent drugs
GAION R.M., MURARI L., CIMA L., VALENTI P., DA RE P. ..... 407

Hypolipaemic effect and inhibition of lipid peroxidation by glunicate in rats on atherogenic diet
FEHÉR J., KISS Á., BLAZOVICS A., SZONDY E., TONCSEV H., MATHIÁSZ D., GERŐ S. ..... 413

**No. 7**

New prospects for research on cephalosporins.
NEUMAN N. ..... 421

The comparative activity of twelve 4-quinolone antimicrobials and sulphadiazine against *Neisseria meningitidis*.
FELMINGHAM D., WALL R.A. ..... 427

The comparative activity of twelve 4-quinolone antimicrobials against Gram-positive and Gram-negative anaerobes.
ROBBINS M.J., O'HARE M.D., FELMINGHAM D., RIDGWAY G.L., GRÜNEBERG R.N. ..... 431

The kinetics in the rat of a new nitroimidazole derivative.
CERRETANI D., RUNCI F.M., SEGRE G. ..... 435

**CEFATRIZINE:** new perspectives in oral antibiotic therapy.

Cefatrizine: a clinical overview.
SANTELLA P.J., TANRISEVER B. ..... 441

Susceptibility of clinical isolates of Gram-positive and Gram-negative organisms to cefatrizine.
CARLONE N.A., CUFFINI A.M., FORNO PIZZOGLIO M., CAVALLO G. ..... 447

Determination of cefatrizine levels in blood, tonsils, paranasal sinuses and middle ear.
SANTACROCE F., DAINELLI B., MIGNINI F., FASANELLA L., MARANGONI F., RIPA S. ..... 453

Determinations of tissue levels of cefatrizine (Zanitrin) in blood, lungs and bronchi.
MIGNINI F., MAGNI A., DAINELLI B., PATRIZI I. ..... 457

New perspectives in oral antibiotic therapy: cefatrizine. Conclusions.
KUEMMERLE H.-P. ..... 461

**No. 8**

Gentisate, a salicylate metabolite with antioxidant properties
CLELAND L.G., WHITEHOUSE M.W., BETTS W.H. ..... 463

Cooper salicylate complex: thermoregulatory and biochemical effects
HAĆ E.E., GAGALO I.T., HAĆ E. ..... 469

The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt
ROOKS W.H. II, MALONEY P.J., SHOTT L.D., SCHULER M.E., SEVELIUS H., STROSBERG A.M., TANENBAUM L., TOMOLONIS A.J., WALLACH M.B., WATERBURY D., YEE J.P. ..... 479

Analysis of the analgesic and anti-inflammatory effects of rimazolium, a pyrido-pyrimidine derivative, compared with that of prostaglandin synthesis inhibitors and morphine
GYIRES K., FÜRST S., MIKLYA I., BUDAVARI I., KNOLL J. ..... 493

Pharmacological properties of a new non-steroidal anti-inflammatory drug: flunoxaprofen
LAMPA E., ROMANO A.R., BERRINO L., TORTORA G., DI GUGLIELMO R., FILIPPELLI A., GENTILE B., MARMO E. ..... 501

Organ tolerance of non-steroidal anti-inflammatory drugs: effect on liver cells
ROSSI F., FILIPPELLI W., GUARINO V., RUSSO S., MAGLIULO R., MARMO E. ..... 511

Plasma and synovial fluid concentrations of isoxicam in meniscectomized patients
BALLERINI R., CASINI A., CHINOL M., MANNUCCI C., MELANI F., UNGAR F. ..... 517

Flumethasone pivalate (Locorten) in the treatment of oral diseases
SCAGLIONE F., FALCHI M., BICHISAO E., FRASCHINI F. ..... 523

**NEW PERSPECTIVES ON UBIQUINONE THERAPY**

*In vitro* effect of different ubiquinones on the scavenging of biologically generated $O_2^-$
LITTARRU G.P., LIPPA S., DE SOLE P., ORADEI A. ..... 529

Inhibitory effects of several anthracyclines on mitochondrial respiration and coenzyme $Q_{10}$ protection
SOLAINI G., RONCA G., BERTELLI A. ..... 533

Research on coenzyme $Q_{10}$ in clinical medicine and in immunomodulation
FOLKERS K., WOLANIUK A. ..... 539

The essentiality of coenzyme Q for bioenergetics and clinical medicine
LENAZ G., FATO R., DEGLI ESPOSTI M., RUGOLO M., PARENTI CASTELLI G. ..... 547

Effect of coenzyme $Q_{10}$ on stress-induced cardiac dysfunction in paediatric patients with mitral valve prolapse: a study by stress echocardiography
ODA T. ..... 557

Effective treatment with coenzyme $Q_{10}$ of patients with chronic myocardial disease
LANGSJOEN P.H., VADHANAVIKIT S., FOLKERS K. ..... 577

Long-term coenzyme $Q_{10}$ therapy: a major advance in the management of resistant myocardial failure
MORTENSEN S.A., VADHANAVIKIT S., BAANDRUP U., FOLKERS K. ..... 581

**No. 9**

Lipid microspheres as novel drug carriers.
MIZUSHIMA Y. ..... 595

Electron microscopic studies on tissue distribution of lipid microspheres used as drug delivery carriers.
SHOJI Y., MIZUSHIMA Y., YANAGAWA A., YONAHA T. ..... 601

Development of a corticosteroid incorporated in lipid microspheres (liposteroid).
YOKOYAMA K., OKAMOTO H., WATANABE M., SUYAMA T., MIZUSHIMA Y. ..... 611

Double-blind study with liposteroid in rheumatoid arthritis.
HOSHI K., MIZUSHIMA Y., SHIOKAWA Y., KAGEYAMA T., HONMA M., KASHIWAZAKI S., SHICHIKAWA K., TSUNEMATSU T., KANEKO K. ..... 621

Prostaglandin $E_1$ incorporated in lipid microspheres (lipo $PGE_1$).
OTOMO S., MIZUSHIMA Y., AIHARA H., YOKOYAMA K., WATANABE M., YANAGAWA A. ..... 627

Recent advances in the use of microspheres for targeted therapy.
DAVIS S.S., HUNNEYBALL I.M., ILLUM L., RATCLIFFE J.H., SMITH A., WILSON C.G. ..... 633

New lipoxygenase inhibitors isolated from Chinese plants. Development of new anti-allergic drugs.
MUROTA S., KOSHIHARA Y. ..... 641

An investigation into the effects of nifedipine and nimodipine on platelet function and vascular prostacyclin synthesis.
JEREMY J.Y., BARRADAS M.A., MIKHAILIDIS D.P., DANDONA P. ..... 645

Antitracheobronchospastic interaction *in vitro* and *in vivo* between salbutamol and fenisolide.
LAMPA E., FILIPPELLI A., PIROZZI A., MATERA C., MARMO E., FANO M., MONTAGNA D., BERNAREGGI V. ..... 653

Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
LUKÁČ J., ROVENSKÝ J., TAUCHMANNOVÁ H., ŽITŇAN D. ..... 659

Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results.
GALLI M., CROCCHIOLO P., NEGRI C., CAREDDA F., LAZZARIN A., MORONI M. ..... 665

The pharmacodynamics of thymomodulin in elderly humans.
CALSINI P., MOCCHEGIANI E., FABRIS N. ..... 671

**No. 10**

Inhibition of Histalog-stimulated gastric secretion by 40 749 RP, a new long-acting gastric anti-secretory agent
BARTHÉLEMY C., WOEHRLÉ R., SIMON J. ..... 675

Digestive tract endoluminal perfusion of cisapride (R 51619) and effects on gastrointestinal hormone levels in anaesthetized pigs
CARUSO U., LEZOCHE E., ELLI M., TISONE G., MARIANI P., D'ALESSANDRO D., CRAVOTTO E., LOMBARDO P.A., TAVOLARO M., SILVAROLI M., CASCIANI C.U. ..... 679

Effect of sulglycotide on gastric bicarbonate secretion in humans
GUSLANDI M., NANNINI D., TITTOBELLO A. ..... 683

Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis
MASCI E., TESTONI P.A., PASSARETTI S., GUSLANDI M., TITTOBELLO A. ..... 687

Hexaprazol antagonism to gastric electrical potential fall by acetylsalicylic acid in rat
LUMACHI B., SCURI R. ..... 693

The effect of cimetidine on the pharmacokinetics of salicylic acid
TRNAVSKÁ Z., TRNAVSKÝ K., ŠMONDRK J. ..... 703

Experimental analysis of antihypertensive properties of S 5984 and its constituents: tertatolol and indapamide
MARMO E., LAMPA E., ROSATTI F., BERRINO L., RUSSO S., ROMANO A.R., MATERA C. ... 709

Efficacy of penbutolol + piretanide combinations in the treatment of arterial hypertension
VERHO M., RANGOONWALA B., PAHNKE K., FREUDE J., HÄRINGER E. ..... 717

Changes in blood pressure and thermographic values resulting from use of a beta-blocker plus diuretic and of an alpha-beta-blocker plus diuretic
DE CESARIS R., GRIMALDI A., BALESTRAZZI M., RANIERI G., CHIARAPPA R., AVANTAGGIATO F. ..... 725

Antipyretic effect of tenoxicam and paracetamol in febrile children
SIMILÄ S., KYLMÄMAA T. ..... 731

Pirprofen in postoperative course following cataract extraction: a controlled trial
SAGGIO F., MONZA G. ..... 735

Evaluation of a new pharmaceutical form of nimesulide for the treatment of influenza
BERNASCONI P., MASSERA E. ..... 739

**No. 11**

Do quinolones really augment the antifungal effect of amphotericin B *in vitro*?
OVERBEEK B.P., ROZENBERG-ARSKA M., VERHOEF J. ..... 745

Dissociated effect of amphotericin B and desoxycholate on phagocytosis of *Escherichia coli* by human polymorphonuclear neutrophils
LINGAAS E., MIDTVEDT T. ..... 747

The organospecific activity of metronidazole and azanidazole in the intrasanguineous host-mediated assay
CANTELLI-FORTI G., HRELIA P., PAOLINI M., BRONZETTI G., BIAGI G.L. ..... 755

Susceptibility of anaerobic bacteria to metronidazole. A bacteriological and clinical study
GUBINA M., RAKOVEC S., SCHOSS-VIDENŠEK Z. ..... 761

Molecular aspects of beta-lactamase inhibition and inactivation by clavulanic acid: a review
LABIA R., BARTHÉLEMY M., PEDUZZI J. ..... 765

Comparative bactericidal and morphological effects of five cephamycins on cells of three Gram-negative bacilli at decreasing drug concentrations
GOI H., WATANABE T., MIYAUCHI K., KAZUNO Y., INOUYE S. ..... 771

Comparative *in vitro* and *in vivo* activity of cefminox (MT-141), cefotaxime and cefoperazone against Gram-negative bacteria
WATANABE T., KAZUNO Y., HIRANO F., INOUYE S., NISHINO T. ..... 781

Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin
FU K.P., VINCE T., McCLOUD S., GREGORY F.J., CHIANG S.T., HUNG P.P. ..... 787

The antibacterial activity of gentamicin in the glucosuric environment
PAPAPETROPOULOU M., GIAMARELLOU H. ..... 793

The effect of calcium on the antibacterial activity of gentamicin in urine
PAPAPETROPOULOU M., GIAMARELLOU H. ..... 797

Norfloxacin concentrations in seminal plasma measured by HPLC
BOLOGNA M., VAGGI L., FLAMMINI D., CARLUCCI G., FRANCAVILLA F. ..... 801

Ticarcillin-clavulanic acid therapy in severe infections
VAN DER AUWERA P., LEGRAND J.C. ..... 805

Treatment of ear, nose and throat infections with cloloctol
GHILARDI P.L., CASANI A. ..... 815

Multivalent treatment of skin diseases in infants and young children
BIANCHI G. ..... 819

**No. 12**

Residual effects of zopiclone and benzodiazepine hypnotics on psychomotor performance related to car driving.
HARRISON C., SUBHAN Z., HINDMARCH I. ..... 823

Minaprine, a new drug with antidepressant properties.
BIZIÈRE K., WORMS P ., KAN J.-P., MANDEL P., GARATTINI S., RONCUCCI R. ..... 831

Midazolam vs lorazepam and placebo as hypnotic premedication before surgery. A controlled, double-blind study.
MATTILA M.A.K., SALMELA J., VÄÄNÄNEN A., KYLMÄMAA T. ..... 841

Flunarizine, cerebral blood flow and reversion of experimental atherosclerosis in rabbit.
FAVALLI L., LANZA E., ROZZA DIONIGI A., ASSOGNA G., GOGGI D., RICEVUTI G. ..... 845

Antihypertensive therapy with diuretics and β-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone.
ROJA M., CUMETTI C., VERGANI A., MONTANARI C., DE CRISTOFARO A. ..... 851

Established latent herpes simplex virus infections of mice not affected by adenosine monophosphate treatment.
KLEIN R.J. ..... 861

Biological properties of benzodifuran derivatives.
VIANO I., DIANZANI C., GIA O., GASTALDI S., GENAZZANI E. ..... 865

Substituted benzaldehyde thiosemicarbazone with antiviral against poliovirus.
ANDREI G.M., PIERONI O.I., GATICA H.S.†, COTO C.E. ..... 869

First experience in the treatment of human hydatid disease with mebendazole.
DE ROSA F., TEGGI A. ..... 875

Clinical assessment of sulbenicillin in acute respiratory tract infection.
MACCHIONI P.L., DEL DIN G., FILIPPI G., BARICCHI R., BERTANI A., PORTIOLO I. ..... 879

Multicentre clinical and bacteriological study of sulbenicillin in patients with bronchopulmonary infection
GINESU F., ORTU A.R., SCHENA G.P., CASALI L., CABIDDU R., TICCA M.A., FODDAI G.A., CARDIA P., LIGIA G.P., TORRAZZA P.L., COGHE M., BANDE G. ..... 885

Results of treatment with sodium sulbenicillin in thirty elderly patients with acute bronchopulmonary infection.
SACCAROLA L., CRISAFI V., CANNIZZARO G., CALVO M.V. ..... 895

Malaria, the growing medical and health problem.
BRUCE-CHWATT L.J. ..... 899